Head-To-Head Contrast: Alexion Pharmaceuticals (ALXN) vs. Auxilium Pharmaceuticals (AUXL)
Alexion Pharmaceuticals (NASDAQ: ALXN) and Auxilium Pharmaceuticals (NASDAQ:AUXL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.
This table compares Alexion Pharmaceuticals and Auxilium Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for Alexion Pharmaceuticals and Auxilium Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Alexion Pharmaceuticals presently has a consensus price target of $155.16, suggesting a potential upside of 27.74%. Given Alexion Pharmaceuticals’ higher probable upside, equities research analysts clearly believe Alexion Pharmaceuticals is more favorable than Auxilium Pharmaceuticals.
Valuation and Earnings
This table compares Alexion Pharmaceuticals and Auxilium Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Alexion Pharmaceuticals||$3.08 billion||8.80||$399.00 million||$2.24||54.22|
Alexion Pharmaceuticals has higher revenue and earnings than Auxilium Pharmaceuticals. Auxilium Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
94.3% of Alexion Pharmaceuticals shares are held by institutional investors. 4.4% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Alexion Pharmaceuticals has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Auxilium Pharmaceuticals has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.
Alexion Pharmaceuticals beats Auxilium Pharmaceuticals on 11 of the 11 factors compared between the two stocks.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
Auxilium Pharmaceuticals Company Profile
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.